retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Retatrutide: The "Triple G" Peptide That Could Rival Bariatric Surgery (And Why You Shouldn't Wait) Retatrutide—A Game Changer in Obesity

5,34 A raised ATP/ADP ratio in beta-cells results in insulin secretion, whereas in alpha-cells an increased ATP/ADP ratio prevents glucagon secretion

It is a 39-amino acid synthetic peptide engineered from a GIP backbone to activate three distinct receptor systems in the body

Side effects may be related to dose, titration speed, meal patterns, hydration, constipation, reflux, or other medications

Patients prescribed a GLP-1 agent should also be encouraged to eat slowly, eat smaller meals and, if needed, adjust the timing of their GLP-1 dose in relation to food intake

Endocrine regulation of male fertility by the skeleton

Med-Spa Appointment Request "*" indicates required fields